

Table F-8. Harms/adverse effects in studies of citalopram

Harm/Adverse Event	N Studies Reporting Harm (# Participants With Harm/Total Participants)	Reported Rates Across Studies
Citalopram hydrobromide		
Agitation/Nervousness/Restlessness ^{100, 101}	1 (13/73)	17.8%
Anxiety ^{100, 101}	1 (8/73)	11%
Appetite increase ^{100, 101}	1 (7/73)	9.6%
Appetite decrease ^{100, 101}	1 (11/73)	15.1%
Attention ^{100, 101}	1 (9/73)	12.3%
Challenging behavior ^{100, 101}	1 (64/73)	87.7%
Energy level changes ^{100, 101}	1 (28/73)	38.4%
GI symptoms ^{100, 101}	1 (46/73)	63%
Headache ^{100, 101}	1 (15/73)	20.5%
Hyperactivity ^{100, 101}	1 (9/73)	12.3%
Infection/Fever/Cold/Congestion symptoms ^{100, 101}	1 (56/73)	76.7%
Insomnia ^{100, 101}	1 (28/73)	38.4%
Nightmares ^{100, 101}	1 (5/73)	6.8%
Repetitive behavior or language ^{100, 101}	1 (8/73)	11%
Seizure ^{100, 101}	1 (2/73)	2.7%
Silliness ^{100, 101}	1 (9/73)	12.3%
Skin changes ^{100, 101}	1 (21/73)	28.8%
Placebo		
Agitation/Nervousness/Restlessness ^{100, 101}	1 (7/76)	9.2%

Harm/Adverse Event	N Studies Reporting Harm (# Participants With Harm/Total Participants)	Reported Rates Across Studies
Anxiety ^{100, 101}	1 (9/76)	11.8%
Appetite increase ^{100, 101}	1 (8/76)	10.5%
Appetite decrease ^{100, 101}	1 (10/76)	13.2%
Attention ^{100, 101}	1 (2/76)	2.6%
Challenging behavior ^{100, 101}	1 (44/76)	57.9%
Energy level changes ^{100, 101}	1 (15/76)	19.7%
GI ^{100, 101}	1 (24/76)	31.5%
Headache ^{100, 101}	1 (10/76)	13.2%
Hyperactivity ^{100, 101}	1 (2/76)	2.6%
Infection/Fever/Cold/Congestion symptoms ^{100, 101}	1 (42/76)	55.3%
Insomnia ^{100, 101}	1 (17/76)	22.4%
Silliness ^{100, 101}	1 (10/76)	13.2%
Skin changes ^{100, 101}	1 (9/76)	11.8%
Somnolence ^{100, 101}	1 (10/76)	13.2%

*Harms reported by more than one participant. GI=gastrointestinal; EPS-extrapyramidal